162 related articles for article (PubMed ID: 17465090)
1. New drugs for the treatment of type 2 diabetes.
Chowdhury TA; Hossain B
Br J Hosp Med (Lond); 2007 Apr; 68(4):178-83. PubMed ID: 17465090
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
3. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control.
Cohen A; Horton ES
Curr Med Res Opin; 2007 Apr; 23(4):905-17. PubMed ID: 17407648
[TBL] [Abstract][Full Text] [Related]
4. Finding new treatments for diabetes--how many, how fast... how good?
Nathan DM
N Engl J Med; 2007 Feb; 356(5):437-40. PubMed ID: 17267901
[No Abstract] [Full Text] [Related]
5. Emerging treatments for patients with type 2 diabetes.
Haines ST
Diabetes Educ; 2007; 33 Suppl 5():105S-10S. PubMed ID: 17548897
[No Abstract] [Full Text] [Related]
6. Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.
Green BD; Flatt PR; Bailey CJ
Diab Vasc Dis Res; 2006 Dec; 3(3):159-65. PubMed ID: 17160910
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Meece J
Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
[TBL] [Abstract][Full Text] [Related]
8. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
9. [New therapies for diabetes: beyond injectable insulin and oral antidiabetics].
Alfonso JE; Ariza ID
Rev Assoc Med Bras (1992); 2008; 54(5):447-54. PubMed ID: 18989567
[TBL] [Abstract][Full Text] [Related]
10. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin: a viewpoint by Mark S. Kipnes.
Kipnes MS
Drugs; 2007; 67(4):598-9. PubMed ID: 17352517
[No Abstract] [Full Text] [Related]
13. Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Gallwitz B
Drugs Today (Barc); 2007 Jan; 43(1):13-25. PubMed ID: 17315049
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes.
Mest HJ; Mentlein R
Diabetologia; 2005 Apr; 48(4):616-20. PubMed ID: 15770466
[TBL] [Abstract][Full Text] [Related]
15. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Winkler G
Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.
Deacon CF
Expert Opin Investig Drugs; 2007 Apr; 16(4):533-45. PubMed ID: 17371200
[TBL] [Abstract][Full Text] [Related]
17. Beyond insulin: what else might help?
Scheiner G
Diabetes Self Manag; 2014; 31(1):30, 32-4. PubMed ID: 24640060
[No Abstract] [Full Text] [Related]
18. Drugs on the horizon for diabesity.
Bailey CJ
Curr Diab Rep; 2005 Oct; 5(5):353-9. PubMed ID: 16188170
[TBL] [Abstract][Full Text] [Related]
19. What are incretins, and how will they influence the management of type 2 diabetes?
Blonde L; Rosenstock J; Triplitt C
J Manag Care Pharm; 2006 Sep; 12(7 Suppl A):S2-12; quiz S14-6. PubMed ID: 16981805
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of current therapies for diabetes mellitus type 2.
Thulé PM
Adv Physiol Educ; 2012 Dec; 36(4):275-83. PubMed ID: 23209008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
